Pharmaceutical industry grows: Trump's trade dispute boosts exports - German Pharma Industry Booms Amid U.S. Tariff Uncertainty
The German pharmaceutical industry is poised for robust growth, with the Association of Research-Based Pharmaceutical Companies (vfa) forecasting a 3.2% increase in production and a 3.4% rise in sales. This growth is partly driven by a tariff dispute with the United States, which has led to increased production and exports. The U.S. market, accounting for around a quarter of German pharmaceutical exports, has been a key catalyst. Earlier this year, the U.S. threatened 100% tariffs on branded and patented drugs, prompting companies to rush shipments and boost production. The threat was later softened to a 15% cap for EU imports. German pharmaceutical giants like Roche, Novartis, Sanofi, and Merck responded to the uncertainty by investing billions in the U.S. in 2021. Despite these shifts, the vfa anticipates continued domestic investment from these companies. The German pharmaceutical sector is projected to see significant growth in production and revenue by 2025. While the U.S. remains a crucial market, domestic investment is expected to continue, supported by a 3.2% increase in production and a 3.4% rise in sales this year.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
- Inspired & Paddy Power Extend Virtual Sports Partnership for UK & Ireland Retail
- South West & South East England: Check & Object to Lorry Operator Licensing Now
